Government Investigates Pharmacy Benefit Manager Profits

In the complex world of American healthcare, Pharmacy Benefit Managers (PBMs) act as powerful intermediaries between drug companies and insurance providers.

Although they were originally designed to manage prescription costs, they are now under intense scrutiny.

Government investigations, led by the Federal Trade Commission (FTC), suggest that the 'Big Three' PBMs—CVS Caremark, Express Scripts, and Optum Rx—wield excessive power over the market.

Following years of investigation, the FTC recently secured a landmark settlement with Express Scripts in 2026, forcing the firm to increase transparency and reform its business practices.

While PBMs maintain that their scale lowers overall costs, patient advocates argue that these 'secretive middlemen' extract massive profits at the expense of affordability.

As the government continues its push for accountability through legislation like the Consolidated Appropriations Act of 2026, the future of drug pricing remains a central topic in U.S. health policy.